HOXB9 promotes epithelial-to-mesenchymal transition via transforming growth factor-β1 pathway in hepatocellular carcinoma cells

Clinical and Experimental Medicine

Volumn 15, Issue 1, 2014, Pages 55-64

  Sha, Lin ^a   Dong, Lei ^a   Lv, Li ^a   Bai, Lizhi ^b   Ji, Xuening ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

Epithelial to mesenchymal transition (EMT); Hepatocellular carcinoma (HCC); Homeobox B9 (HOXB9); Transforming growth factor 1 (TGF 1)

Indexed keywords

HOMEODOMAIN PROTEIN; HOXB9 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANTAGONISTS AND INHIBITORS; CELL MOTION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTAGONISTS AND INHIBITORS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HEP G2 CELLS; HOMEODOMAIN PROTEINS; HUMANS; METABOLISM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84963948834     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-014-0276-7     Document Type: Article

References (36)

1. Bruix J, Boix L, Sala M, Llovet JM (2004) Focus on hepatocellular carcinoma. Cancer Cell 5(3):215–219
2. Zaret KS (2002) Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet 3(7):499–512
3. Lai E, Prezioso VR, Tao WF, Chen WS, Darnell JE Jr (1991) Hepatocyte nuclear factor 3 alpha belongs to a gene family in mammals that is homologous to the Drosophila homeotic gene fork head. Genes Dev 5(3):416–427
4. Bossard P, Zaret KS (1998) GATA transcription factors as potentiators of gut endoderm differentiation. Development 125(24):4909–4917
5. Abate-Shen C (2002) Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2(10):777–785
6. Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, Meyer C, Rosenwald A, Drexler HG, MacLeod RA (2007) Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 109(7):3015–3023
7. Nunes FD, de Almeida FC, Tucci R, de Sousa SC (2003) Homeobox genes: a molecular link between development and cancer. Pesqui Odontol Bras 17(1):94–98
8. Cantile M, Cindolo L, Napodano G, Altieri V, Cillo C (2003) Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas. Oncogene 22(41):6462–6468
9. Chen F, Capecchi MR (1999) Paralogous mouse Hox genes, Hoxa9, Hoxb9, and Hoxd9, function together to control development of the mammary gland in response to pregnancy. Proc Natl Acad Sci USA 96(2):541–546
10. Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK (2003) Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 63(18):5879–5888
11. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138(1):51–62
12. Vider BZ, Zimber A, Hirsch D, Estlein D, Chastre E, Prevot S, Gespach C, Yaniv A, Gazit A (1997) Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression. Biochem Biophys Res Commun 232(3):742–748
13. Shrestha B, Ansari KI, Bhan A, Kasiri S, Hussain I, Mandal SS (2012) Homeodomain-containing protein HOXB9 regulates expression of growth and angiogenic factors, facilitates tumor growth in vitro and is overexpressed in breast cancer tissue. FEBS J 279(19):3715–3726
14. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco M, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S (2010) HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 107(3):1100–1105
15. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Investig 119(6):1420–1428
16. Franco-Chuaire ML, Magda Carolina SC, Chuaire-Noack L (2013) Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin 54(2):186–205
17. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, Labarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G (2014) CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res 74(2):520–531
18. Lim J, Thiery JP (2012) Epithelial-mesenchymal transitions: insights from development. Development 139(19):3471–3486
19. Le Bras GF, Taubenslag KJ, Andl CD (2012) The regulation of cell–cell adhesion during epithelial-mesenchymal transition, motility and tumor progression. Cell Adh Migr 6(4):365–373
20. Gomes LR, Terra LF, Sogayar MC, Labriola L (2011) Epithelial-mesenchymal transition: implications in cancer progression and metastasis. Curr Pharm Biotechnol 12(11):1881–1890
21. Katsuno Y, Lamouille S, Derynck R (2013) TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25(1):76–84
22. Drabsch Y, ten Dijke P (2012) TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31(3–4):553–568
23. Fuxe J, Karlsson MC (2012) TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 22(5–6):455–461
24. Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, Wen P, Yang J (2012) The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 302(3):F369–F379
25. Naber HP, Drabsch Y, Snaar-Jagalska BE, ten Dijke P, van Laar T (2013) Snail and Slug, key regulators of TGF-beta-induced EMT, are sufficient for the induction of single-cell invasion. Biochem Biophys Res Commun 435(1):58–63
26. Kang H, Lee M, Jang SW (2013) Celastrol inhibits TGF-beta1-induced epithelial-mesenchymal transition by inhibiting Snail and regulating E-cadherin expression. Biochem Biophys Res Commun 437(4):550–556
27. Sun VC, Sarna L (2008) Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs 12(5):759–766
28. Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR, Roberts LR (2011) Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 9(7):617–623.e611
29. Cabrera R, Nelson DR (2010) Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 31(4):461–476
30. Chang AC, Fu Y, Garside VC, Niessen K, Chang L, Fuller M, Setiadi A, Smrz J, Kyle A, Minchinton A, Marra M, Hoodless PA, Karsan A (2011) Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase. Dev Cell 21(2):288–300
31. Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24(50):7443–7454
32. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715
33. Lai W, Liu L, Zeng Y, Wu H, Xu H, Chen S, Chu Z (2013) KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer. Med Oncol 30(2):566
34. Na DC, Lee JE, Yoo JE, Oh BK, Choi GH, Park YN (2011) Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp Mol Pathol 90(1):66–73
35. Zheng X, Gai X, Wu Z, Liu Q, Yao Y (2013) Metastasin leads to poor prognosis of hepatocellular carcinoma through partly inducing EMT. Oncol Rep 29(5):1811–1818
36. Kapur RP, Gershon MD, Milla PJ, Pachnis V (2004) The influence of Hox genes and three intercellular signalling pathways on enteric neuromuscular development. Neurogastroenterol Motil 16(Suppl 1):8–13